Ligand Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Ligand Pharmaceuticals Incorporated

22/02/2023 22:02

* Ligand Pharmaceuticals Inc  LGND.OQ  reported quarterly
adjusted
earnings of $1.36​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was
for earnings of $1.19 per share.
    * Revenue fell 35.1% to $47.04 million from a year ago;
analysts
expected $46.64 million. 
    * Ligand Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.04​.
    * The mean earnings estimate of analysts had risen by
about 21.3%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Ligand Pharmaceuticals Inc shares had risen by 6.1% this
quarter.
    * The company reported a quarterly loss of $17.49 million.
    * Wall Street's median 12-month price target for Ligand
Pharmaceuticals Inc is $107.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
22 at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      1.19           1.36           Beat
 Sep. 30 2022      0.43           1.31           Beat
 Jun. 30 2022      0.43           1.03           Beat
 Mar. 31 2022      0.66           0.58           Missed